---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-098482"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2023-04-12T23:59:59+00:00"
generated_at: "2026-06-17T03:06:03.539560+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics COO Carrie Melvin departs effective April 11, 2023

## Summary
- Carrie Melvin ceased as COO effective April 11, 2023; severance benefits provided per employment agreement.
- Severance treated as involuntary not-for-cause termination, subject to release and restrictive covenants.
- No replacement named in the filing; succession plans not disclosed.

## SEC filing metadata
- accession: 0001193125-23-098482
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2023-04-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312523098482/0001193125-23-098482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312523098482/d460755d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-098482
- JSON: https://secwatch.observer/filing/0001193125-23-098482.json
- Plain text: https://secwatch.observer/filing/0001193125-23-098482.txt

## Key facts
- Executive change
  Carrie Melvin departed as Chief Operating Officer at Viridian Therapeutics, Inc.\DE.
  - Action: ceased to serve
  - Role: Chief Operating Officer
  source text: On April 12, 2023, Viridian Therapeutics, Inc. (the “Company”) announced that Carrie Melvin has ceased to serve as the Company’s Chief Operating Officer, effective April 11, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523098482/0001193125-23-098482-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.